Recent progress in our understanding of the immunologic basis of allergic diseases has suggested that enhanced production of the cytokines IL-4 and IL-13 by allergen-specific T cells is responsible for increased IgE synthesis and the development of allergic disease in certain individuals. Based on these observations, it is clear that approaches to inhibition of allergen-specific IgE synthesis should be aimed at blocking the activation or preventing the synthesis ofIL-4 and IL-13. In the present review, two approaches toward this goal are discussed.
Recent progress in our understanding of the immunologic basis of allergic diseases has suggested that enhanced production of the cytokines IL-4 and IL-13 by allergen-specific T cells is responsible for increased IgE synthesis and the development of allergic disease in certain individuals. Based on these observations, it is clear that approaches to inhibition of allergen-specific IgE synthesis should be aimed at blocking the activation or preventing the synthesis ofIL-4 and IL-13. In the present review, two approaches toward this goal are discussed.
First, an IL-4 mutant protein is described that acts as a powerful antagonist of both IL-4 and IL-13 activity, including induction of IgE synthesis by these cytokines in vitro.
A llergen-specific IgE antibodies play an important role in mediating allergic reactions. They bind to high-affinity IgE receptors (FCERI) expressed on mastcells and basophils. Binding of allergens to this receptorbound IgE results in receptor activation that triggers the mastcells/basophils to release soluble mediators such as histamines, leukotrienes, prostaglandins, and proteases, which cause allergic reactions in various target organs, including the eyes, respiratory tract, intestines, and skin.
Early studies have shown that Ig production, including IgE synthesis, is T-helper-cell dependent [1] , but only recently it has become clear that cytokines play an important role in Ig production [2] . They determine Ig production quantitatively through their B-cell growth and differentiation inducing effects. In addition, cytokines direct the quality of the Ig isotype produced, because they determine Ig isotype switching. For example, the T-cell-derived interleukins (IL)-4 and IL-13 induce human B cells to produce IgG4 and IgE [3] , whereas TGF-fi induces IgA switching [4] . In addition to cytokines, contact-mediated co-stimulatory signals delivered by activated CD4+ T -helper cells are required for induction of Ig production both in vitro and in vivo [5] .
In the present communication, cellular and molecular aspects of induction and regulation of human IgE synthesis and the role of allergen-specific T cells and cytokines produced by these cells will be discussed. In addition, novel approaches to intervene in early stages of the regulatory processes, which lead to induction of IgE synthesis, and their potential clinical utility will be described. Second, it is demonstrated that T-cell clones can be rendered non-responsive following incubation with allergen-derived peptides representing minimal T-cell activation-inducing epitopes. These non-responsive T cells fail to produce IL-4 and IL-13 and to proliferate following subsequent activation with the relevant allergen and antigen-presenting cells. In addition, these non-responsive T cells fail to provide B-cell help for IgE synthesis. It is tempting to speculate that induction of non-responsiveness in allergen-specific T-cell clones by allergen-derived immunogenic peptides may provide the basis for successful desensitization of allergic patients.] [,west DermatoI102:141-144,1994 lL-4 AND IL-13 INDUCE IGG4 AND IGE SYNTHESIS B cells undergo Ig isotype switching and differentiation into Ig secreting cells in response to antigens that specifically bind to surface IgM receptors and co-stimulatory signals delivered by CD4+ T -helper cells. Antigen-specific T -B interactions require binding of the T-cell receptor to peptide class II major histocompatibility antigens (MHC) complexes on the B cells, which results in T-cell activation and cytokine production. Once T-helper cells are activated, they can stimulate B cells to proliferate and to differentiate in an antigen-dependent fashion. Cytokines play an essential role in these processes. IL-4, which is produced by T cells and mast-cells, induces IgE synthesis in cultures of mononuclear cells of peripheral or cord blood, tonsils, and spleens [3] . Single naive surface IgM+, IgD+ B cells can be induced to produce IgG4 and IgE, in the presence of activated CD4+ T -helper cells and IL-4, indicating that IgG4 and IgE production reflects Ig isotype switching [6] . In addition, these data suggested that during clonal expansion switching of a proportion of the B cells may proceed in two successive steps: from IgM to IgG4 and from IgG4 to IgE. The fact that Ig production in these cultures is restricted to IgM, IgG4, and IgE furthermore indicates that isotype switching is not a stochastic process but is directed by the way the B cells are activated.
Recently, we cloned, expressed, and characterized another T-cell-derived cytokine, IL-13 [7] , which was found to induce IgG4 and IgE production by human B cells in an IL-4-independent manner [8] ' Interestingly, mouse IL-13 failed to induce IgE synthesis by mouse B cells in culture systems where IL-4 was effective. This is compatible with the observation that mice in which the IL-4 gene is disrupted by homologous recombination fail to produce IgE following parasite infections [9] . Thus IL-13 is only effective in inducing human IgE synthesis. Whether this implies that IL-13 plays a unique role in inducing IgE-mediated allergic diseases remains to be determined and depends on the relative contributions of lL-13 and IL-4 to this process.
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IL-4/IL-13-INDUCED IgE ,SYNTHESIS REQUIRES CO-STIMULATORY SIGNALS PROVIDED BY T-B CELL CONTACTS
In addition to cytokines, contact-mediated co-stim';llatory ~ignals delivered by activated CD4+ T -helper cells are requtred for mduction ofIg production in vivo [5, 10, 11] . These T-B ~ell contacts are mediated through interactions between the CD40 hgand (CD40L) (which is transiently expressed on activate~ T cells) and CD. 
IgE SYNTHESIS IN VIVO
Murine studies have indicated that IL-4 is responsible for IgE production in vivo, because parasite-infected mice treated with neutralizing anti-IL-4 antibodies failed to produc~ IgE [16] . Howeve~, no circulating IL-4 or IL-13 could be detected.m .the ~er~m of p~tients with very high serum IgE levels, but convmcmg md1rect. eV1?enCe has been obtained, indicating that enhanced IL-4 production 1S also associated with elevated serum IgE levels in humans [17] . For example, peripheral blood mononuclear cells (PBMe) of som~ pa~ients with high serum IgE ~evels spontaneously produce IL-4 In vI,tr~, a phenomenon that is never observed wit~ PBMC of non-atop1c mdividuals. In addition, PBMC of such patients produce levels ofIL-4 following activation that are significantly higher than those produced by PBMC of normal control donors [16] . t:he fail':ll'e to.dete~t measureable levels of circulating IL-4 and IL-13 m atop1c patients 1S probably related to the fact th~t these ~ytokines are biologi~a~ly active at femtomolar concentrations, wh1ch are below the sens1t1v-ity of, the detection assays and that they are predominan,tly produced at the site of allergic reactions. Indeed, T cells producmg IL-4 and IL-5 have been identified in situ in skin biopsies taken from late-phase cutaneous reactions .in at~pic asthma I?atients [18] or in bronchial lavage fluids of atop1c patients, followmg allergen challenge [19] . . Recent information has shown that allergen-speCific T cells are responsible for the enhanced levels of IL-4 production in allergic patients. Allergen-specific CD4+ T cells established from allergic patients gen. erally ~elong to the T-helper cell 2 (Th2) subset, producing relattvely h1gh levels ofIL-4, IL-5, and IL-13 and no, or low levels of, IFN-y after allergen-specific activation in vitro. 
Interferon (IFN}-Y and IFN-a are also effective in reducing serum IgE levels in vivo. Administration of I~N-y o. r lPN-a to patients with the hyper IgE syndrome resulted m a rap1d, but transient, reduction in serum IgE levels, whereas the serum levels of the other Ig isotypes in these patients remained unaffected ~20,21]. !n the single patient treated with IFN-a, complete but translent remlssion of the skin lesions associated with this syndrome was observed, despite her serum IgE levels still being elevated as compared to those of normal controls [21] . Such case reports, however, indicate that the use of IFN-y and/or IFN-a for the treatment of severe atopic diseases, like atopic dermatitis, deserves further exploration.
AN IL-4 ANTAGONIST INHIBITS BOTH IL-4 AND IL-13-INDUCED IgE SYNTHESIS
Although the relative contribution of IL-4 and IL-l3 to IgE production ill vivo remains to be determined, it is clear that effective inhibition of IgE synthesis in vivo requires prevention or inhibition of both IL-4 and IL-13 production by allergen-specific T cells, or blocking of the activity of these cytokines by using specific IL-4 and IL-l3 antagonists. Recently an IL-4 mutant protein has been described that binds with high affinity to the IL-4 receptor (IL-4R), without receptor activation [22, 23] . Interestingly, this IL-4 mutant protein, in which the tyrosine residu~ at po~iti?~ 124 is replaced by an aspartic acid (IL-4.Yl24D), effectively mhlb1ts both IL-4-and IL-l3-induced IgG4 and IgE synthesis in vitro [24] . A lO-50-fold molar excess of IL-4.Y124D inhibited IgE synthesis by optimal IL-4 and IL-l3 concentrations by >95%, indicating that IL-4. Y124D acts as a powerful antagonist for both IL-4 and IL-13 activity. Although IL-13 competes with IL-4 for binding to functional IL-4R and vice versa, it does not bind to the cloned 130-kD IL-4 receptor expressed on heterologous cells. In addition, the affinity of IL-4 for its functional "wild type" receptor is higher than that for the cloned IL-4R. These, and other data, have led to the conclusion that the IL-4 and IL-13R are complex receptors that share a common component, which confers high-affinity binding for IL-4, and which is required for signal transduction [23] . The observation that the IL-4 antagonist inhibited both IL-4 -and IL-13 -induced IgE production in vitro supports this notion. Therefore, antagonistic IL-4 mutant proteins may provide the most efficient way to reduce IgE synthesis in allergic patient~ and may have thera~eutical p.ote~ tial for the treatment of allerg1es. However, more mformatlon 1S required regarding the stability and the effects of these molecules in vivo.
INDUCTION OF NON-RESPONSIVENESS IN ALLERGEN-SPECIFIC T CELLS IN VITRO
The most specific approach to prevent allergen-specific IgE synthesis in vivo should be aimed at rendering allergen-specific T cells non-responsive to allergen challenge. Such non-responsive T cells will not proliferate and will not produce IL-4 and IL-13 in response to subsequent activation by allergen and antigen-presenting cells (APe), which will result in prevention of allergen-specific IgE synthesis in vivo. The minimal requirement for an allergen-specific immune response is effective binding ofT -cell receptors on allergen-specific T cells to allergen-derived peptide-class II MHC complexes on APC. Whether these T-cell-receptor peptide/MHC complex interactions result in T-cell activation depends on co-stimulatory signals provided by "professional" APC. TCR-peptide/MHC complex interactions in the absence of co-stimulatoty signals delivered by professional APC renders these cells non-responsive to subsequent challenges by antigens and APC [25, 26] .
Human T cells can also be tolerized iI, vitro following activation with supra immunogenic doses of antigenic peptides in the absence of professional APC. Subsequent exposure of these ~olerize? T c~lls to antigens presented by APC does not result m prohferatton [27, 32] . Because anergic T-cell clones fail to produce IL-2, de-creased production of this cytokine by the T cells has been proposed as the mechanism of clonal non-responsiveness [25, 26] .
Similar observations were made with allergen-specific human T-cell clones. Incubation of T -cell clones specific for the major house dust mite allergen Der pi with supra immunogenic doses of Der pI-derived pep tides (representing the minimal T-cell activation inducing epitopes) in vitro rendered these clones non-responsive to subsequent stimulation by whole Der pi and APC. The nonresponsive state was associated with the strong downregulation of T-cell receptors, suggesting that in this situation reduced TCR expression may account for the non-responsiveness of these cells." The observation that stimulation of these T-cell clones via their TCR failed to induce significant intercellular Ca++ fluxes is compatible with this notion. In contrast to their non-tolerized counterparts, the "tolerized" Der pI specific T cells failed to produce cytokines, including IL-4 and IL-13, and to induce IgE synthesis when co-cultured with purified B cells, indicating that these cells also lost their B-cell helper activity resulting in IgE switching and IgE production.
INDUCTION OF TOLERANCE IN VIVO
Immunotherapy with immunogenic pep tides corresponding to immuno-dominant T-cell determinants administered to mice can induce T-cell tolerance to subsequent challenge with native antigens in vivo. Such pep tides have recently been successfully used to treat autoimmune disease in mice. For example, tolerance-inducing regimens for the treatment of myeloid basic protein induced autoimmune encephalitis (EAE), blocked the progression and decreased the severity of EAE, after the disease had begun. The peptide-induced tolerance resulted from the induction of anergy in proliferative, antigen-specific T cells [32] . Comparable data have recently been obtained with allergen-derived peptides. Administration of two peptides, which contain some, but not all, T-cell epitopes on one of the chains of the cat allergen Fel dI also decrease the T-cell responses to this entire chain of Fel dl in mice [32] .
PEPTIDE VACCINATION IN ALLERGIC PATIENTS
The potential use of peptide induced T-cell tolerance as a means to treat severe human allergies is a consequence of these studies. The question, however, is how to proceed. As mentioned ~bove, allergen-specific T-cell clones can be rendered non-responsive to subsequent allergen challenges it' vitro by incubation with supra immunogenic doses of antigenic peptides in the absence of professional APC. In addition, traditional immunotherapy (IT) with standardized allergen extracts seems to become more effective, when patients are desensitized with increasing (maximally tolerated) concentrations of allergens. Although it remains to be established, it is tempting to speculate that mechanisms resulting in peptide-induced allergen-specific T-cell non-responsiveness also may account for successful IT. Therefore, based on the present information, ideally one would like to administer high concentrations of allergen-derived peptides, containing T-cell activation inducing epitopes, to bypass the professional APC and to " hit" the allergen-specific T cells directly and render them anergic. Theoretically this is feasible, because pep tides containing minimal T -cell-inducing epitopes do not react with specific IgE antibodies and do not induce histamine release from sensitized basophils, and thus are unable to induce anaphylactic reactions (H. Y ssel et al, unpublished). Therefore, such peptides seem to be ideal tools for inducing allergen-specific T-cell tolerance. A major problem, however, is that most, if not all, allergens contain multiple T-cell activation inducing (T-cell epitopes) epitopes, which are restricted by various class II MHC molecules [33] [34] [35] . This implies that for each patient all "individual" T-cell inducing epitopes should be determined together with precise human leukocyte antigen typing. Such an approach is, at this stage, impractical and cannot be carried out on a large scale for general treatment of allergies. However, the principles of this type of IT could be worked out in individual, well-defined patients.
A more practical approach could be the use of overlapping peptides of approximately 30 -50 amino acids, representing whole known (recombinant) allergens that can be produced at an industrial scale. Assuming that such peptides contain all the T-cell epitopes of the corresponding allergen, administration of high concentrations of these mixtures of allergen-derived peptides seems feasible without inducing anaphylaxis. The advantage of this approach is that it does not require mapping of minimal T-cell activation inducing epitopes. In addition, there is no necessity of class II MHC typing of the patients. One clinical trial, which is in part based on this type of approach, is presently in progress. In this trial, patients with cat allergies are treated with two Fel dl -derived peptides representing the immunodominant T-cell epitopes.
CONCLUDING REMARKS
Treatment of allergies is presently predominantly focused on late phases of the allergic response, namely, an inhibition of mediator release by mastcells or basophils or on blocking of binding of soluble mediators to their receptors. The present data indicate that enhanced IL-4 and IL-13 production by allergen-specific T cells is associated with enhanced allergen-specific serum IgE levels. Therefore, it is clear that novel approaches to block IgE synthesis in an early stage should be aimed at the inhibition, or neutralization, of IL-4 and IL-13 production in vivo by using IL-4 and IL-13 antagonists like IL-4 mutant protein or derivatives thereof, described here. However, much more information is required about the stability of such antagonistic proteins and their activities it, vivo.
The mechanisms by which high IL-4-and IL-13-producing allergen-specific CD4+ T cells are selected in atopic patients remains to be elucidated. A better understanding of these selection mechanisms will enable us to define ways to intervene in these processes, and to reduce the frequencies of high IL-4-and IL-13-producing T cells. One possible way is to render these T cells nonresponsive by administration of mixtures of allergen-derived peptides, representing all T-cell activation inducing epitopes on the corresponding allergen. As discussed here, such peptides induce T-cell unresponsiveness, and fail to provide B-cell help, resulting in IgE synthesis in vitro. They also induce a state of T-cell unresponsiveness in mice it, vivo. Because these pep tides do not react with IgE antibodies and thus are unable to induce anaphylactic reactions, they seem to be ideal tools for inducing specific T-cell tolerance it' vivo.
The outcome of the clinical trial with the Fel dl -derived peptides will provide more information about the efficacy and safety of such therapies, although it has to be kept in mind that this trial is carried out with only two peptides containing "immunodominant" T-ceJl epitopes, whereas the Fel dl molecules contain many more T-cell epitopes, which may prevent efficient tolerance induction in all patients.
